At first glance, sperm appear to be relatively unremarkable cells churned out by the body. They are small, stripped of most cellular machinery, and produced in staggeringly large numbers – upwards of 1,500 per second in a healthy adult male. Yet beneath this apparent simplicity lies an immunological paradox that has fascinated researchers for over a century: most sperm bear several antigens that are completely foreign to the body that makes them.
The discovery that sperm were relative foreigners to the body was made in 1899. At this time, Austrian-born immunologist Karl Landsteiner, best known for discovering the ABO blood group system, observed that injecting sperm from one animal into another could elicit an immune response. Later work showed that injecting mice with genetically matched testicular germ cells could induce autoimmunity even without any adjuvants, impairing fertility. Decades later, these observations were formalized into the concept of immune privilege, a term describing select anatomical sites where the immune system operates under a different set of rules. Alongside the brain, the eye, and the placenta, the testes joined this short list of tissues where immune tolerance is actively enforced rather than passively assumed. The reason that sperm require this protection ultimately comes down to location. Spermatogenesis, or sperm cell development, is restricted to the testes, and sperm proteins are not expressed in the thymus. Central tolerance to sperm proteins is thus not generated, making sperm vulnerable to attack if recognized as foreign invaders.
The unique architectural design of the testes enables them to minimize this potential threat. Lining the seminiferous tubules, where sperm are produced, are Sertoli cells, which “nurse” developing sperm and whose tight junctions form what is known as the blood-testis barrier. This physical seal excludes circulating immune cells and antibodies from ever reaching the maturing germ cells in the interior. This barrier is not permanent, though. As developing sperm migrate inward through the tubule wall, the junctions must briefly open and reseal, a process that creates fleeting windows of vulnerability to immune attack. Sertoli cells compensate for this vulnerability by releasing immunosuppressive cytokines to dampen immune activity in the vicinity.
Equally critical to maintaining immune privilege in the testes are tissue-resident macrophages. Macrophages populate the interstitial space between the seminiferous tubules alongside testosterone-producing Leydig cells. Here, these cells support testosterone production, while testosterone in turn keeps macrophages tolerant. This pro-tolerogenic environment also promotes the local maintenance of regulatory T cells, which suppress any adaptive immune response against sperm antigens that leak out of the tubules. In these ways, the testes maintain an anatomical and immunological niche to keep newly developing sperm cells safe from destruction.
The immunological niche in the testes poses a unique risk for the development of neoplasia. Cancer cells can hijack the immunosuppressive niche within the testicular microenvironment to promote the formation of germ cell tumours, which are the most common solid malignancy in males between 15 and 35. These tumors are thought to arise from developmentally arrested germ cells, which leverage the testicular immunosuppressive niche to avoid early immune detection.
The carefully maintained immunological equilibrium is easily disrupted by inflammation in the testes, or orchitis. Infection with the mumps virus is the most well-known culprit and causes orchitis in up to 30% of post-pubertal males. This threatens them with testicular atrophy and lasting impairments in fertility. Bacterial infections ascending from the urogenital tract, including those caused by common urogenital pathogens such as Chlamydia trachomatis and Escherichia coli, can do the same. During inflammation, pro-inflammatory cytokines disrupt the tight junctions holding the blood-testis barrier together, and immune cells flood into the seminiferous tubules. The ensuing collateral damage to maturing germ cells can be severe and permanent. In this way, the immune response mounted to fight urogenital infections often becomes the primary source of lasting tissue destruction.
Repair and regeneration in the testes are possible when inflammation is minor: inflammatory cells recede, allowing the blood-testis barrier to repair itself. However, recovery in the testes is slow. While inflammatory symptoms of orchitis may fade within days to weeks, sperm production is dependent on a months-long developmental cycle, so fertility lags behind. The deciding factor is whether the barrier is repaired before sperm antigens provoke a lasting immune response.
Repeated or sustained damage sets off a threatening chain of events that compromises successful repair. Chronic infection and inflammation, as well as physical trauma, testicular torsion, and even vasectomy, can disrupt the normal sequestration of sperm antigens and expose them to the immune system. Once exposed to sperm antigens that are normally sequestered from the immune system, the body may mount an immune response and produce anti-sperm antibodies. Anti-sperm antibodies are found in 9 to 36% of infertile men and interfere with fertility at multiple steps, reducing sperm motility and blocking penetration of the egg. Inflammatory fibrosis accompanying chronic orchitis can further obstruct the seminiferous tubules entirely, preventing sperm from being generated.
Autoimmune orchitis, while rare, offers a direct clinical view of the consequences of the collapse of immune tolerance in the testes. It thus remains a key model for understanding immunological male infertility, a diagnosis that is still frequently overlooked in practice. Better characterization of anti-sperm antibody profiles may offer new diagnostic footholds for men whose infertility currently has no clear explanation. Their reported prevalence varies widely depending on the population and test used. Moreover, the presence of these antibodies does not always prove they are the cause of infertility. This makes immunological infertility both clinically important and easy to miss. Current research is therefore moving toward classifying male infertility as discrete diagnoses that result from unresolved inflammation, barrier leak, autoantibodies, fibrosis, oxidative stress, or a failure of immune repair.
The testes also sit at the centre of an important modern question in infectious disease: can immune privilege turn an organ into a viral sanctuary? Several viruses – including Zika virus and SARS-CoV-2 – can infect the male reproductive tract, where they may persist. Robust changes in semen quality are also observed post-viral infection, and research is focused on studying whether these reflect direct testicular infection, fever, systemic inflammation, vascular injury, or some combination of these. Evidence is still mixed, and many sperm changes after febrile illness are likely transient over a spermatogenic cycle. However, given that the testes themselves are an immunologically silent niche, important work is being conducted to ask whether they may act as long-lived reservoirs for dangerous viral infections.
Testicular immunologists today are also exploring whether the mechanisms that sustain testicular immune privilege can be deliberately manipulated to enhance fertility. Declining levels of testosterone with age appear to reshape the composition and behaviour of testicular immune cells, with implications for both fertility and disease susceptibility. Sperm quality, testicular structure, Leydig-cell function, and testosterone production decline gradually with age. As testosterone maintains the immunosuppressive macrophage niche, its decline reduces the ability of the local macrophage–Leydig–Sertoli cell circuit to restore tolerance after injury. In this rapidly evolving model, age-related male infertility is a problem of both declining sperm production and a failure of immunological resilience.
The next frontier in treating infertility lies in repair and rejuvenation. If inflammation opens the blood–testis barrier and compromises testicular function, how may we intervene to help close it again before tolerance is lost? The way forward relies on understanding the signals that restore Sertoli cell junctions, restrain damaging immune responses, prevent fibrosis, and preserve spermatogonial stem cells after infection and injury. Clinically, while fertility preservation is already central for patients facing gonadotoxic treatment, inflammatory and immunological infertility is still harder to predict, diagnose, and treat. Further innovation in testicular immunology will allow us to intervene before a temporary inflammatory episode becomes permanent reproductive failure.
Jonathan Monteiro
Latest posts by Jonathan Monteiro (see all)
- Sex Differences in Osteoimmunology - October 5, 2026
- The Delicate Immunology of the Testes - October 5, 2026
- Primates: Better Models for Human Disease? Opportunities and Challenges - May 24, 2026
